TB-500 lab monitoring
Which blood work to run before, during and after a TB-500 cycle, and what the research can and can't tell you about the results. TB-500 is a 7-amino-acid fragment of thymosin beta-4 (Tβ4) (PMID 22962027). No human study of the fragment has been published, and FDA says it has not identified any human exposure data for it. That's even less than BPC-157 has. So this panel is a safety baseline built from full-length Tβ4 and rat data. It doesn't prove the peptide is working.
When to test
1. Baseline (before you start)
| Marker | Why test it | Standard range |
|---|---|---|
| ALT Alanine aminotransferase | No study has tested TB-500 itself on the liver. Its parent protein, full-length thymosin beta-4 (Tβ4), lowered ALT and AST after chemical liver injury in mice and rats (PMID 28724974) and protected the liver in an alcohol injury model (PMID 30116499). With no human data on the fragment, your own baseline is the only reference point. | 0-45 IU/L Tighter target: 29-33 men, 19-25 women (ACG 2017 healthy upper limit) Source: Cleveland Clinic |
| AST Aspartate aminotransferase | Read alongside ALT. AST is also found in muscle, so a hard training session in the days before the draw can raise it on its own. | 0-35 IU/L Source: Cleveland Clinic |
| Creatinine Serum creatinine | There is no human data on how TB-500 is cleared. In rats given TB-500, its breakdown products showed up in urine, mainly Ac-LK in the first 6 hours (PMID 38382158). Kidney markers here are a general safety baseline, not a known risk: no kidney toxicity has been reported. | 0.76-1.27 men, 0.57-1.00 women mg/dL Source: Labcorp |
| eGFR Estimated glomerular filtration rate | Calculated from creatinine; it shows how well your kidneys filter. | Above 90 mL/min/1.73m² Source: UK Kidney Association |
| hs-CRP High-sensitivity C-reactive protein | A general inflammation baseline. Full-length Tβ4 lowered TNF-alpha and IL-6 gene expression in a mouse liver-injury model (PMID 30116499), and in coronavirus-infected mice recombinant Tβ4 left serum CRP unchanged (PMID 33967626). No study has measured CRP after dosing TB-500 itself. | Under 1.00 low risk, 1.00-3.00 average, over 3.00 high mg/L Source: Labcorp |
| ESR Erythrocyte sedimentation rate | A second, slower-moving inflammation marker to pair with hs-CRP. No TB-500 or Tβ4 study has measured ESR. | Men 0-15 (under 50), 0-30 (50+); women 0-32 (under 50), 0-40 (50+) mm/hour Source: Labcorp |
| CBC Complete blood count | A standard safety baseline before any injectable. FDA lists immunogenicity risk for TB-500 from aggregation and peptide-related impurities. The two phase 1 trials of full-length Tβ4 reported no serious adverse events (PMID 20536472, PMID 34346165). | WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL Source: Cleveland Clinic |
2. Mid-cycle (week 4)
tracking only, no expected direction
| Marker | Why test it |
|---|---|
| hs-CRP High-sensitivity C-reactive protein | Tracks inflammation against your baseline. Most useful if your baseline was raised. |
| ESR Erythrocyte sedimentation rate | Paired with hs-CRP. A sharp rise during a cycle is worth a clinician's look. |
3. Post-cycle (2-4 weeks after your last dose)
| Marker | Why test it |
|---|---|
| ALT Alanine aminotransferase | Confirms liver enzymes stayed in range across the cycle. |
| AST Aspartate aminotransferase | Read with ALT; skip hard training for a couple of days before the draw. |
| Creatinine Serum creatinine | Confirms kidney markers stayed in range. |
| eGFR Estimated glomerular filtration rate | Read with creatinine. |
| hs-CRP High-sensitivity C-reactive protein | Compare with baseline and week 4. |
| ESR Erythrocyte sedimentation rate | Compare with baseline and week 4. |
Ranges differ between labs, and by sex and age. Labcorp publishes its creatinine, ESR and hs-CRP ranges but not its AST, ALT or CBC ranges, so those come from Cleveland Clinic. Your own report's printed range is the one to read against.
What to expect
-
ALT and AST: expected to stay in range (baseline to post-cycle)
There is no human data on TB-500 at all. Full-length Tβ4 protected the liver in mice and rats (PMID 28724974, PMID 30116499), and its two phase 1 trials in healthy volunteers reported no serious adverse events or dose-limiting toxicities (PMID 20536472, PMID 34346165). Those trials used the full protein IV, not TB-500.
If it doesn't: A rise above range is not something the research predicts. Stop, retest, and look at what else is in the picture: other compounds in a stack, alcohol, medications, recent hard training (AST), or a vial that isn't what its label says.
-
Creatinine and eGFR: expected to stay in range (baseline to post-cycle)
No kidney toxicity has been reported for TB-500 or Tβ4. Rats given TB-500 passed its breakdown products in urine (PMID 38382158).
If it doesn't: A drop in eGFR or rise in creatinine is not predicted by the research. Stop and retest with a clinician.
-
hs-CRP and ESR: no established change (baseline, week 4, post-cycle)
No study has measured CRP or ESR after dosing TB-500. The closest data: recombinant Tβ4 left serum CRP unchanged in coronavirus-infected mice (PMID 33967626), and full-length Tβ4 lowered TNF-alpha and IL-6 gene expression in injured mice (PMID 30116499). If your baseline is normal, expect it to stay normal.
If it doesn't: A flat CRP does not mean your TB-500 is fake, and a falling one doesn't prove it's real. Inflammation markers move for many reasons (training, illness, sleep, diet). A clear rise is worth a clinician's look.
Your labs can't check your vial
No blood test can confirm what's in your vial. FDA's compounding safety review says compounded thymosin beta-4 fragment (LKKTETQ), also known as TB-500, "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities," and that FDA "has not identified any human exposure data" for it. Anti-doping chemists identified the 7-amino-acid fragment in a product sold as TB-500 (PMID 22962027), but no published study has tested grey-market TB-500 for purity. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.
What the research doesn't show
- No human study of TB-500 has been published, and FDA says it has not identified any human exposure data. Everything on this page is borrowed from full-length Tβ4 or from rats.
- The human data that does exist is for full-length Tβ4 given IV: two phase 1 trials in healthy volunteers, 40 people for up to 14 days and 84 people for up to 10 days (PMID 20536472, PMID 34346165). Results from full-length Tβ4 products are not TB-500 results.
- CRP has been measured only in mice given full-length Tβ4, with no change (PMID 33967626); CRP and ESR have never been measured after dosing TB-500.
- Banned in sport: thymosin beta-4 and its derivatives such as TB-500 have been named as prohibited growth factors (S2.3) on the WADA Prohibited List since 2018.
Sources
- Cleveland Clinic: Liver function tests (ALT, AST normal ranges)
- Kwo PY, et al. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017. PMID 27995906
- Labcorp test 001370: Creatinine (reference range)
- UK Kidney Association: CKD staging (eGFR)
- Labcorp test 120766: C-reactive protein, high sensitivity (cardiac risk tiers)
- Pearson TA, et al. Markers of inflammation and cardiovascular disease (AHA/CDC). Circulation 2003. PMID 12551878
- Labcorp test 005215: Sedimentation rate, erythrocyte (reference range)
- Cleveland Clinic: Complete blood count (normal values for adults)
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal 2012. PMID 22962027
- Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats. J Chromatogr B 2024. PMID 38382158
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. PMID 20536472
- Wang X, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med 2021. PMID 34346165
- Li X, et al. Effects of exogenous thymosin β4 on carbon tetrachloride-induced liver injury and fibrosis. Sci Rep 2017. PMID 28724974
- Shah R, et al. Thymosin β4 prevents oxidative stress, inflammation, and fibrosis in ethanol- and LPS-induced liver injury in mice. Oxid Med Cell Longev 2018. PMID 30116499
- Jo JO, et al. Thymosin β4 induces the expression of VEGF in a HIF-1α-dependent manner. Biochim Biophys Acta 2010. PMID 20691219
- Cha HJ, et al. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003. PMID 14625258
- Lee SY, et al. Increased expression of thymosin β4 is independently correlated with HIF-1α and worse clinical outcome in human colorectal cancer. J Pathol Transl Med 2017. PMID 27744656
- Caers J, et al. Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica 2010. PMID 19833631
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (thymosin beta-4 fragment, TB-500)
- USADA: 2018 Prohibited List summary of major changes (thymosin beta-4 and TB-500 added under S2.3)
Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.